← Back to Search

Gold compound

Pharmacological Study for Non-Small Cell Lung Cancer

Phase 1 & 2

Waitlist Available

Led By Panos Savvides, M.D., Ph.D.

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will study the effects of auranofin and sirolimus on patients with lung cancer.

Eligible Conditions

Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Lung Adenocarcinoma
Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

MTD of auranofin (Phase I)

Number and severity of all adverse events (Phase I)

Progression-free survival rate (Phase II)

Secondary outcome measures

Duration of response

Overall response rate, defined to be either a complete response (CR) or partial response (PR) noted as the objective status

Progression-free survival time

+1 more

Other outcome measures

Change in protein kinase C (PKC) iota protein expression

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (auranofin and sirolimus)Experimental Treatment4 Interventions

Patients receive auranofin PO on days 1-28 and sirolimus PO on days 1-28 (days 8-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Sirolimus

2013

Completed Phase 4

~2750

Auranofin

2016

Completed Phase 2

~180

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,207 Previous Clinical Trials

3,766,831 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,660 Previous Clinical Trials

40,924,243 Total Patients Enrolled

Panos Savvides, M.D., Ph.D.Principal InvestigatorMayo Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any patients currently enrolled in this research?

"That is correct. The information available from clinicaltrials.gov indicates that this study, which was established on 11/29/2012, is still looking for patients. Up to 47 individuals are needed across 1 site."

Answered by AI

How many individuals are being recruited for this experiment?

"That is accurate, the listing on clinicaltrials.gov says that this trial is still looking for volunteers. The original posting was on 11/29/2012 and there have been updates as recently as 6/27/2022. Currently, they are seeking 47 individuals total from 1 site."

Answered by AI

Are there other examples of this sort of pill-based research?

"At the moment, there are a 130 different ongoing studies researching Pharmacological Study. Out of those, 13 are currently in Phase 3. Most trials for Pharmacological Study take place in Cincinnati, Ohio; however, there are 1084 total locations where one could find an active trial.."

Answered by AI

What is the average condition that Pharmacological Study is prescribed for?

"Pharmacological Study is most effective in treating transplant rejection and liver disease. Additionally, it has shown some utility in managing rheumatoid arthritis, kidney disease, and other conditions."

Answered by AI

Recent research and studies

ChemMedChemJournal

Conception and Evaluation of Fluorescent Phosphine‐gold Complexes: From Synthesis to in Vivo Investigations

Rousselle, Benjamin, Aurélie Massot, Malorie Privat, Lucile Dondaine, Audrey Trommenschlager, Florence Bouyer, Jérôme Bayardon, et al.. 2022. “Conception and Evaluation of Fluorescent Phosphine‐gold Complexes: From Synthesis to in Vivo Investigations”. Chemmedchem. Wiley. doi:10.1002/cmdc.202100773.

clinicaltrials.govStudy

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

2014. "Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01737502.